Akademik Veri Yönetim Sistemi
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, cilt.41, sa.2, ss.1-11, 2025 (SCI-Expanded)
Mantle Cell Lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma (NHL), accounting for 5–7% of all lymphomas. Currently, there is no standardized treatment option for older patients (>65 years), and optimizing MCL treatment in this group remains a signifcant clinical challenge. In this multicenter retrospective study, we aimed to evaluate the outcomes of frst-line treatments, overall survival (OS), progression-free survival (PFS), and factors infuencing survival in patients aged 65 years and older diagnosed with MCL. Patients aged≥65 years diagnosed with MCL between November 2016 and January 2024 in six centers were included in this study. A total of 77 patients were included in the study, with 60 males (77.9%) and 17 females (22.1%). The median age was 71 years (range: 65–89). At diagnosis, 96.1% of patients had Stage III-IV disease, and 36.4% had an ECOG performance score of 2–3. Based on the MIPI-c score, 48% of patients had high-risk disease. As induction chemotherapy, 44.2% received R-CHOP, 13% received RB, 13% received R-CVP, and 29.8% received alternating R-CHOP/R-DHA-platinum. Additionally, 19.5% of patients underwent ASCT, and 28.6% received Rituximab maintenance after induction therapy or ASCT. The overall response rate (ORR) was 71.4%. After a median follow-up of 32 months, the median PFS was 18 months, and the median OS was 42 months. In multivariate analysis, independent risk factors for inferior PFS were LDH>ULN (HR: 2.09, 95% CI: 1.05–4.16, p=0.035), Ki67≥30% (HR: 2.90, 95% CI: 1.38–6.10, p=0.005), blastoid variant (HR: 1.86, 95% CI: 1.09–5.12, p=0.040), and maintenance treatment (HR: 0.31, 95% CI: 0.12–0.75, p=0.010). Independent risk factors for inferior OS were the maintenance treatment (HR: 0.29, 95% CI: 0.09–0.94, p=0.040) and POD24 (HR: 2.04, 95% CI: 1.06–4.19, p=0.044). There remains no universally accepted standard treatment for older MCL patients, and the disease remains incurable with current treatment modalities. However, advancements in targeted therapies and the optimization of maintenance strategies hold promise for improving survival in older and unft patients. Future studies focusing on incorporating targeted therapies into frst-line treatment and identifying high-risk factors that infuence survival will be crucial in tailoring efective and individualized treatment approaches for this population.